In a groundbreaking study unveiled by researchers at the Francis Crick Institute, a novel neuroimmune mechanism has been identified that plays a pivotal role in shaping the immune response against lung cancer. The research, published in the prestigious journal Cell, reveals how sensory nerve signals actively modulate the tumor microenvironment and thereby influence cancer progression, opening new avenues for enhancing immunotherapy efficacy.
This investigative endeavor focused on the intricate communications within the tumor microenvironment, a complex cellular ecosystem surrounding cancer cells. While the immune system’s cellular constituents have long been studied for their roles in either suppressing or facilitating tumor growth, the influence of nervous system components has remained enigmatic. The Crick Institute team addressed this gap by examining how specialized sensory nerves, which typically detect environmental threats such as noxious heat, physical damage, or chemical irritants, interact with immune cells within lung tumors.
Utilizing sophisticated mouse models, the researchers meticulously manipulated the activity of these sensory nerves, observing pronounced effects on tumor dynamics. Notably, sensory nerve activation bolstered tumor growth, whereas their inhibition correlated with reduced cancer progression. This bidirectional relationship was further characterized by the tumors’ capacity to induce nerve proliferation and stimulate the release of the neuropeptide calcitonin gene-related peptide (CGRP), a key molecular mediator in this neuroimmune dialogue.
CGRP emerged as a crucial suppressor of immune defense mechanisms in the tumor milieu. The study demonstrated that CGRP acts on tumor-associated macrophages, immune cells integral to the orchestration of antitumor responses, impeding the formation of tertiary lymphoid structures (TLS). TLS are organized clusters of immune cells renowned for their association with improved patient prognosis across various cancers, including lung carcinoma. By hindering TLS development, CGRP effectively diminishes the immune system’s capacity to mount a robust and coordinated attack against neoplastic cells.
Importantly, therapeutic interventions that either disrupted the sensory nerve signals or blocked CGRP receptors reinstated TLS formation within tumors. This immunological restructuring intensified the antitumor immune response, resulting in substantial suppression of tumor growth. Given that CGRP receptor antagonists are already utilized clinically for the treatment of migraine headache, the translational potential of repurposing these drugs for cancer therapy is both compelling and immediate.
Extending their inquiry to environmental factors, the Crick team explored the impact of cigarette smoke—a dominant risk factor for lung cancer—on this neuroimmune interface. Exposure to cigarette smoke extract was found to amplify sensory neuronal activity, thereby accelerating tumor advancement. This insight reveals an understudied pathway by which smoking exacerbates cancer progression, beyond its well-known genotoxic effects, by harnessing nerve-mediated immune suppression.
The implications of these findings extend far beyond a single malignancy. They challenge the classical paradigms of tumor immunology by integrating neuroscience, illustrating that nerve fibers and their signaling molecules are not merely bystanders but active architects in the tumor microenvironment. This intersection of disciplines suggests that cancer treatment strategies could be revolutionized by targeting neuroimmune interactions, thereby enabling modulation of the immune landscape in favor of tumor eradication.
Leanne Li, leading the Cancer-Neuroscience Laboratory at the Crick Institute, emphasized the transformative potential of these discoveries: “Our work underscores the complexity of the tumor microenvironment, revealing how neuronal components influence immune cell behavior and tumor progression. This intersection of neuroscience and immunology represents a fertile ground for innovative therapeutic development.”
Co-first authors Ya-Hsuan Ho and Giacomo Bregni further highlighted the clinical ramifications of the study. Ho noted, “Our observations that neuronal activity can reorganize the immune architecture within tumors challenge existing concepts of immune evasion in cancer.” Bregni added, “Despite advancements in immunotherapy, many lung cancer patients do not benefit due to resistance mechanisms. Targeting neuroimmune pathways offers a previously unrecognized strategy to enhance treatment responses.”
This research serves as the foundation for future work by the InteroCANCEption team, an interdisciplinary consortium funded with up to £20 million through the Cancer Grand Challenges initiative. Their mission is to decode how the nervous system’s sensory capabilities—interoception—detect tumors and modulate cancer progression. By mapping neural pathways and brain activity patterns linked to tumor signaling, the team aims to translate neurobiological insights into novel diagnostics and therapies encompassing neural modulation techniques.
Dr. David Scott, Director of Cancer Grand Challenges, reflected on the significance of harnessing the nervous system to intervene in cancer development: “Exploring how brain-tumor communications influence disease offers an exciting frontier. Funding teams like InteroCANCEption catalyzes transformative breakthroughs that redefine the boundaries of oncology and neuroscience.”
The revelation that sensory neurons and their secreted factors contribute dynamically to immune suppression within tumors not only reshapes our understanding of lung cancer biology but also signals a turning point in cancer research. Therapeutic targeting of neuroimmune crosstalk, particularly leveraging existing pharmacological agents that inhibit CGRP signaling, holds promise for augmenting immunotherapy efficacy, which remains suboptimal for many patients.
Moreover, the identification of cigarette smoke’s role in modulating this neuroimmune nexus provides a molecular explanation for the exacerbation of lung cancer progression by smoking. This newfound knowledge underlines the urgency of integrating preventative measures with innovative therapeutic strategies to confront lung cancer—a disease that continues to pose substantial global health challenges.
In summary, the Francis Crick Institute’s landmark study charts a new path by elucidating how sensory nerve signals regulate immune architecture in lung cancer and identifying CGRP as a key inhibitory messenger. The potential to repurpose CGRP receptor antagonists to reinvigorate antitumor immunity offers a compelling translational direction. As neuroscience and immunology converge, future cancer treatments may harness the nervous system’s influence to tip the balance against malignancy, transforming patient outcomes in the years to come.
Subject of Research: The neuroimmune interactions between sensory nerves and immune cells within the lung tumor microenvironment and their implications for cancer progression and therapy.
Article Title: Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer.
News Publication Date: Tuesday, May 19, 2026.
References: Ho et al. (2026). Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer. Cell.
